ORIC Pharmaceuticals, Inc. has announced promising preliminary efficacy and safety data from its ongoing Phase 1b trial of ORIC-944. The trial involves combining ORIC-944 with androgen receptor inhibitors in patients with metastatic castration-resistant prostate cancer (mCRPC). The study reported a 59% PSA50 response rate, with a confirmed rate of 47%, and a 24% confirmed PSA90 response rate. PSA responses were consistent across all dose levels and in combination with both apalutamide and darolutamide. The safety profile of the drug combination was compatible with long-term dosing, with most adverse events being Grade 1 or 2. ORIC Pharmaceuticals also announced a $125 million financing, extending its cash runway into the second half of 2027. The company plans to initiate its first global registrational trial in the first half of 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.